Courtesy of Benzinga.
Analysts at Jefferies initiated coverage on Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) with a Buy rating.
The target price for Bellicum Pharmaceuticals is set to $35.
Bellicum Pharmaceuticals’ shares jumped 10.86% to close at $31.75 on Friday.
Latest Ratings for BLCM
Date | Firm | Action | From | To |
---|---|---|---|---|
Jan 2015 | Jefferies | Initiates Coverage on | Buy | |
Jan 2015 | Piper Jaffray | Initiates Coverage on | Overweight | |
Jan 2015 | Jefferies | Initiates Coverage on |
View More Analyst Ratings for BLCM
View the Latest Analyst Ratings
Posted-In: JefferiesInitiation Analyst Ratings